Company: MBIO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001104659-25-009408
Chunk: 2

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 2
---
 Stock2,203,856 Series C-1 Warrants to Purchase up to 2,203,856 Shares of Common Stock

2,203,856 Series C-2 Warrants to Purchase up to 2,203,856 Shares of Common Stock

Placement Agent Warrants to Purchase up to 132,231 Shares of Common Stock

Up to 6,743,799 Shares of Common Stock Issuable Upon Exercise ofthe Series C-1 Warrants, Series C-2 Warrants, Pre-funded Warrants and Placement Agent Warrants</div>

We are offering up to 2,203,856 shares of common stock, together with accompanying Series C-1 warrants (the “Series C-1 Warrants”) to purchase up to 2,203,856 shares of common stock, and Series C-2 warrants (the “Series C-2 Warrants” and together with the Series C-1 Warrants, the “Warrants”) to purchase up to 2,203,856 shares of common stock, pursuant to this prospectus. The combined assumed public offering price for each share of common stock, together with one Series C-1 Warrant and one Series C-2 Warrant, each to purchase one share of common stock, is $3.63, which is equal to the last reported sale price of our common stock on the Nasdaq Capital Market on February 4, 2025. The shares of common stock and Warrants will be separately issued. Each Warrant will have an exercise price of $ per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants (“Warrant Stockholder Approval”), provided, however, if the Pricing Conditions (as defined below) are met, the Warrants will be exercisable upon issuance (the “Initial Exercise Date”). The Series C-1 Warrant will expire on the five-year anniversary of the Initial Exercise Date. The Series C-2 Warrant will expire on the twenty-four-month anniversary of the Initial Exercise Date. As used herein “Pricing Conditions” mean that the combined offering price per share and accompanying Warrants is such that the Warrant Stockholder Approval is not required under the rules of The Nasdaq Stock Market LLC (“Nasdaq”) because either (i) the offering is an at-the-market offering under Nasdaq rules and such price equals or exceeds the sum of (a) the applicable “Minimum Price” per share under Nasdaq Rule 5635